Drugs / Gemtuzumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06713837 | Feb 2025 → Jan 2028 expected | acute myeloid leukemia | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01041040 | Oct 2007 → Dec 2012 | acute myeloid leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06448013 Background | Mar 2025 → Dec 2028 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05716009 Background | Nov 2023 → May 2025 | acute myeloid leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gemtuzumab | “This is an open-label Phase Ia/Ib clinical study of tagraxofusp-erzs, a novel cytokine-drug conjugate that links interleukin-3 with a truncated diphtheria toxin, in combination...” NCT05716009 ↗3“Single agent Gemtuzumab or Gemtuzumab in combination with alone or in combination with low dose hypomethylating agent or low dose cytarabine” NCT06713837 ↗ |
| Known as | Gemtuzumab component of mylotarg | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108342 ↗ |
| Known as | Hp 67.6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108342 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2108342 ↗ |
| Route | Intravenous | “Given by IV” NCT06448013 ↗ |
| Target | CD33 | “Myeloid cell surface antigen CD33 binding agent” CHEMBL2108342 ↗ |